GRAIL, Inc.

General Information
Business:

We are a healthcare company focused on saving lives and improving health by pioneering new technologies for early cancer detection.

Our multi-cancer early detection blood test, Galleri, is designed as a screening test for asymptomatic individuals over 50 years of age. We plan to commercially launch Galleri in 2021 as a laboratory developed test. In a clinical study, an earlier version of Galleri identified over 50 types of cancers, over 45 of which lack recommended screenings. (These cancers include cancer of the bladder, the anorectal area, the esophagus, the pancreas , the liver, the ovary and the uterus, as well as melanoma.) Data showed that when our test detected a cancer, it was also able to localize the cancer signal with high accuracy.

Industry: Services - Medical Laboratories
Employees: 436
Founded: 2015
Contact Information
Address 1525 O’Brien Drive Menlo Park, California 94025
Phone Number (650) 542-0372
Web Address https://grail.com/
View Prospectus: GRAIL, Inc.
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-264.1 mil (last 12 months)
IPO Profile
Symbol GRAL
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Morgan Stanley/ Goldman Sachs/ BofA Securities/ Cowen/ Evercore ISI
CO-Managers
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change